ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Analysis

ZyVersa Therapeutics (NASDAQ:ZVSA) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares ZyVersa Therapeutics and Nurix Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Risk & Volatility

ZyVersa Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ZyVersa Therapeutics and Nurix Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0	0	0	0	0.00
Nurix Therapeutics	1	1	13	1	2.88

Nurix Therapeutics has a consensus price target of $32.14, suggesting a potential upside of 88.30%. Given Nurix Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than ZyVersa Therapeutics.

Valuation & Earnings

This table compares ZyVersa Therapeutics and Nurix Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41 million	($0.83)	-0.23
Nurix Therapeutics	$83.98 million	21.02	-$264.46 million	($3.16)	-5.40

ZyVersa Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Nurix Therapeutics beats ZyVersa Therapeutics on 8 of the 14 factors compared between the two stocks.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.